How have you been incorporating Abemaciclib into the adjuvant management of high risk node positive HR+ breast cancer?

To date, I have used local lab results for Ki-67 and had no issues with insurance coverage. Our breast team has otherwise been attempting to utilize abemacicilib in situations that meet the monarch-E protocol (Patients with four or more positive nodes, or one to three nodes and either tumor size ≥ 5...